Chair and CEO Trigg Leslie was granted 99,419 shares and sold $52,189 worth of shares (65,236 units at $0.80), increasing direct ownership by 4% to 895,580 units (SEC Form 4)

$OM
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $OM alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Trigg Leslie

(Last) (First) (Middle)
3052 ORCHARD DRIVE

(Street)
SAN JOSE CA 95134

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chair and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/17/2025 A 99,419(1) A $0.0 960,816 D
Common Stock 01/21/2025 S 4,403(2) D $0.8 956,413 D
Common Stock 01/21/2025 S 42,384(3) D $0.8 914,029 D
Common Stock 01/21/2025 S 18,449(4) D $0.8 895,580 D
Common Stock 8,770 I Trigg Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On January 6, 2023, the reporting person was granted performance-based restricted stock units (PSUs) subject to the satisfaction of specified performance criteria as of December 31, 2024. The reported amount represents the number of PSUs earned by the reporting person on January 17, 2025, upon certification by the Compensation Committee of the Issuer's Board of Directors of the satisfaction of specified performance criteria. Each PSU represents a contingent right to receive a share of common stock. These PSUs vested 50% on January 17, 2025, and the remaining 50% shall vest on December 31, 2025, subject to the reporting person's continuous service through the vesting period.
2. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with 11,706 shares of Common Stock underlying PSUs which (i) were, as previously reported, granted to the reporting person on February 2, 2022, (ii) were earned as of January 26, 2024 as certified by the Compensation Committee of the Issuer's Board of Directors of the satisfaction of specified performance criteria, and (iii) vested and were released on January 17, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
3. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with 100,000 shares of Common Stock underlying PRSUs which (i) represent 50% of the target shares underlying the original award (granted on January 12, 2024, as previously reported), which were earned based on performance as of December 31, 2024, upon certification by the Compensation Committee of the Issuer's Board of Directors, and (ii) vested and were released on January 17, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
4. Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 50% of the PSUs, described in footnote (1) above, on January 17, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
By: John L Brottem For: Leslie Trigg 01/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $OM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OM

DatePrice TargetRatingAnalyst
8/8/2024$6.00 → $3.00Outperform → Sector Perform
RBC Capital Mkts
6/21/2024$5.00 → $6.00Sector Perform → Outperform
RBC Capital Mkts
4/8/2024$6.00Buy
BTIG Research
4/5/2024$6.00Neutral → Buy
CL King
1/12/2024$14.00 → $6.00Outperform → Sector Perform
RBC Capital Mkts
10/13/2023$32.00 → $3.00Buy → Underperform
BofA Securities
8/17/2023Neutral
CL King
11/11/2022$23.00Outperform
RBC Capital Mkts
More analyst ratings

$OM
Press Releases

Fastest customizable press release news feed in the world

See more
  • Outset Medical Announces One-for-Fifteen Reverse Stock Split

    SAN JOSE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced a one-for-fifteen reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Thursday, March 20, 2025. The Company's common stock will continue to trade under Outset's existing trading symbol, OM, on the Nasdaq Global Select Market ("Nasdaq") on a split-adjusted basis when the market opens on Thursday, March 20, 2025, with the new CUSIP number 6901452

    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Outset Medical to Present at the 45th Annual TD Cowen Health Care Conference

    SAN JOSE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 45th annual TD Cowen Health Care conference on Tuesday, March 4, 2025, at 2:30 p.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc.Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo®

    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results

    SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5% (37.7% on a non-GAAP basis) in the fourth quarter increased 220 basis points sequentially from the third quarter and 11 percentage points from the fourth quarter of 2023. Gross margi

    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$OM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OM
SEC Filings

See more

$OM
Leadership Updates

Live Leadership Updates

See more
  • Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments
  • Outset Medical Names Business Leader Dale E. Jones to Board of Directors

    Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking

    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • EBR Systems Appoints Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler to the Board of Directors

    Renowned MedTech leaders join EBR Board of Directors Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems' Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems' Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler  EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced the appointment of Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler to the Board as Independent Non-Executive Directors. D

    $MDT
    $OM
    $RMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

$OM
Financials

Live finance-specific insights

See more
  • Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results

    SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5% (37.7% on a non-GAAP basis) in the fourth quarter increased 220 basis points sequentially from the third quarter and 11 percentage points from the fourth quarter of 2023. Gross margi

    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Outset Medical to Report Fourth Quarter and Full-Year 2024 Financial Results on Wednesday, February 19, 2025

    SAN JOSE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2024 after the close of trading on Wednesday, February 19, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:

    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Outset Medical to Report Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

    SAN JOSE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, November 6, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Easte

    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$OM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more